Australia's most trusted
source of pharma news
Friday, 13 September 2024
Posted 22 August 2024 PM
Eli Lilly has generated some astonishing results that will raise a lot of questions for the diabetes market.
The pharma announced the topline results from its SURMOUNT-1 study, where tirzepatide, the active ingredient in diabetes drug Mounjaro and obesity drug Zepbound, reduced the chance of progression to diabetes in overweight or obese adults by an astonishing 94 per cent.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.